What Is the Status of Personalized Immunosuppression
THURSDAY, SEPT. 11, 2014
Michael Abecassis. MD, MBA, Northwestern University Feinberg School of Medicine
Long-term graft and patient survival are the key issues in transplantation. Liver transplantation is potentially a curative treatment for hepatocellular carcinoma (HCC). However, disease recurrence is the main challenge to the success of this treatment. Immunosuppressants that are universally used after transplantation to prevent graft rejection could potentially have a significant impact on HCC recurrence. This session will discuss the potential effects of different types of immunosuppressants on HCC recurrence and the role of personalized immunosuppressants used for patients transplanted with HCC.
- Define personalized Immunosuppression.
- State potential effects of different types of immunosuppressants on HCC recurrence.
These materials are intended ONLY for pharmacists and pharmacy technicians that attended the presentation, "What Is the Status of Personalized Immunosuppression?" held at 3:30 p.m. Thur., Sept. 11, 2014. This session was part of the "23rd Annual National Conference" held in Chicago, Ill. on Sept. 10-12, 2014.
The prerequisite to this process is completing the 23rd Annual National Conference Post-Assessment and Evaluation. If there is a Prerequisite section above and the Status field is blank, click on '23rd Annual National Conference' to open the Assessment and Evaluation.
- 0.75 ACPE - Pharmacist